很不错的初步结果了 Chinese Covid-19 Vaccine Is 86% Effective https://www.wsj.com/articles/chinese-vaccine-is-86-effective-in-protecting-against-covid-19-u-a-e-trial-shows-11607498200 DUBAI—A Chinese vaccine candidate showed to be 86% effective in protecting people against Covid-19 in late-stage trials, the United Arab Emirates said, a positive sign for the fight against the virus in the developing world. However, health experts cautioned that more information was needed on the Phase 3 trials. The efficacy rate announced by authorities in the U.A.E., where the trials took place, would put the vaccine above the 50% threshold that international scientists deem necessary to protect people. Candidates developed by Moderna Inc. and jointly by Pfizer Inc. and BioNTech SE have shown to have efficacy rates of 94.5% and 95% in the final stages of testing, respectively. The U.A.E. Health Ministry didn’t disclose how many trial participants developed Covid-19 and how many of those received a placebo or a vaccine. It also wasn’t known whether the data was peer reviewed. The results were the first from Phase 3 trials of a Chinese Covid-19 vaccine. Nearly one million Chinese people have already received the shot, which was developed by state-owned drugmaker Sinopharm, after the government granted emergency-use authorization for it in July. Public-health experts said that the headline figure suggested that the world had another working vaccine option, although more details were needed. Some questioned why Sinopharm hadn’t jointly presented the results. COVID-19 VACCINES What to Know About the U.K. CampaignFDA Says Pfizer-BioNTech Vaccine Meets Success CriteriaTakeaways: The Pfizer-BioNTech Vaccine ReportsOnce Vaccinated, How Do You Prove It?Vaccine Passports Could Help Life Return to Normal, but Experts Urge Caution “I think it’s great news but it’s a little unusual not to come from the study manufacturer,” said Jerome Kim, director of the International Vaccine Institute in Seoul. Among the details that Mr. Kim said were still needed were confidence intervals that could give the public a sense of how reliable the efficacy estimate was. “There are just so many questions around the way it’s been presented.” A U.A.E. official involved in the trial didn’t immediately respond to a request for further information. Sinopharm didn’t respond to a request for comment. The U.A.E. said it had registered the vaccine, paving the way for its wider use, having approved it for emergency use in September. The U.A.E. government and Sinopharm haven’t disclosed the financial details of their trial partnership. The trial began in July, involving about 31,000 volunteers and two different strains of the vaccine. The U.A.E. had previously said one-third of the trial’s participants got a placebo and the remaining two-thirds were administered one of the two strains—one developed in Beijing and another in Wuhan. The U.A.E. said the Beijing strain was 86% effective. It wasn’t known whether an analysis was conducted on the Wuhan strain. What China and Russia Could Reap From Covid-19 Vaccine Diplomacy YOU MAY ALSO LIKE UP NEXT
0:00 / 6:11
5:17
What China and Russia Could Reap From Covid-19 Vaccine Diplomacy As wealthier countries buy up supplies of Western drugmakers’ Covid-19 vaccines that are still in development, China and Russia are offering their fast-tracked shots to poorer nations. Here’s what they're hoping to get in return. Illustration: Ksenia Shaikhutdinova While some people who received the vaccine got infected, it said the shot was 100% effective in preventing moderate or severe cases of the disease. The analysis also showed 99% of participants analyzed developed antibodies against the disease. An 86% efficacy rate makes Sinopharm’s vaccine a potential candidate for many countries in emerging markets that can’t immediately gain access to vaccines from the West. Bahrain has already approved emergency use of the vaccine, while China is also testing the candidate in Egypt, Argentina, Jordan, Peru and other countries. Countries running clinical trials generally have a head start in evaluating the vaccine for use by their own people. While Western governments are focused on launching vaccines within their own borders, Chinese officials have talked about sharing their shot in an effort aimed in part at strengthening diplomatic ties. STAY INFORMED Get a coronavirus briefing six days a week, and a weekly Health newsletter once the crisis abates: Sign up here. The candidate developed by Sinopharm, or China National Pharmaceuticals Group, is based on an inactivated virus, meaning that the pathogen is weakened for use on humans. It can be stored at regular refrigerator temperatures, unlike the Pfizer-BioNTech and Moderna vaccines, making it an attractive option for poorer countries lacking cold-chain infrastructure. Sinopharm previously said that among the nearly one million Chinese people who have been vaccinated, only a few of the people experienced mild symptoms and not a single person had a serious adverse reaction. The U.A.E. has already inoculated tens of thousands of residents with the Sinopharm vaccine since September, offering it to airport staff, teachers and government officials, including police officers, judiciary employees and 30,000 armed forces personnel. U.A.E. officials have said that none have gotten sick with Covid-19. By contrast, Western companies sought government approvals to market their candidates to the public once clinical trials were complete. China has three other Covid-19 experimental vaccines in late-stage trials. Brazil, which is testing Sinovac Biotech Ltd.’s CoronaVac, is expected to release efficacy results in the coming days. Results from early clinical trials of CoronaVac showed that it induced antibodies in volunteers, although at lower levels than those seen in people who were previously infected with Covid-19. China has had to venture overseas to conduct clinical trials on its vaccines as it has successfully controlled the coronavirus at home. Sinopharm executives have said the U.A.E. was chosen for trials due to its diverse population: Only about 10% of the country’s nearly 10 million residents are Emiratis, with the remainder largely from Asia, Europe and the U.S. Corrections & Amplifications An earlier version of this article misspelled Pfizer. Also, an earlier version of this article incorrectly identified Dubai’s ruler, Sheikh Mohammed bin Rashid Al-Maktoum, as crown prince in the photo caption. He is a former crown prince. (Corrected on Dec. 9, 2020)
DUBAI—A Chinese vaccine candidate showed to be 86% effective in protecting people against Covid-19 in late-stage trials, the United Arab Emirates said, a positive sign for the fight against the virus in the developing world. However, health experts cautioned that more information was needed on the Phase 3 trials. The efficacy rate announced by authorities in the U.A.E., where the trials took place, would put the vaccine above the 50% threshold that international scientists deem necessary to protect people. Candidates developed by Moderna Inc. and jointly by Pfizer Inc. and BioNTech SE have shown to have efficacy rates of 94.5% and 95% in the final stages of testing, respectively. The U.A.E. Health Ministry didn’t disclose how many trial participants developed Covid-19 and how many of those received a placebo or a vaccine. It also wasn’t known whether the data was peer reviewed. The results were the first from Phase 3 trials of a Chinese Covid-19 vaccine. Nearly one million Chinese people have already received the shot, which was developed by state-owned drugmaker Sinopharm, after the government granted emergency-use authorization for it in July. Public-health experts said that the headline figure suggested that the world had another working vaccine option, although more details were needed. Some questioned why Sinopharm hadn’t jointly presented the results. COVID-19 VACCINES What to Know About the U.K. Campaign FDA Says Pfizer-BioNTech Vaccine Meets Success Criteria Takeaways: The Pfizer-BioNTech Vaccine Reports Once Vaccinated, How Do You Prove It? Vaccine Passports Could Help Life Return to Normal, but Experts Urge Caution “I think it’s great news but it’s a little unusual not to come from the study manufacturer,” said Jerome Kim, director of the International Vaccine Institute in Seoul. Among the details that Mr. Kim said were still needed were confidence intervals that could give the public a sense of how reliable the efficacy estimate was. “There are just so many questions around the way it’s been presented.” A U.A.E. official involved in the trial didn’t immediately respond to a request for further information. Sinopharm didn’t respond to a request for comment. The U.A.E. said it had registered the vaccine, paving the way for its wider use, having approved it for emergency use in September. The U.A.E. government and Sinopharm haven’t disclosed the financial details of their trial partnership. The trial began in July, involving about 31,000 volunteers and two different strains of the vaccine. The U.A.E. had previously said one-third of the trial’s participants got a placebo and the remaining two-thirds were administered one of the two strains—one developed in Beijing and another in Wuhan. The U.A.E. said the Beijing strain was 86% effective. It wasn’t known whether an analysis was conducted on the Wuhan strain.
What China and Russia Could Reap From Covid-19 Vaccine Diplomacy YOU MAY ALSO LIKE
UP NEXT
0:00 / 6:11
5:17
The U.A.E. has already inoculated tens of thousands of residents with the Sinopharm vaccine since September, offering it to airport staff, teachers and government officials, including police officers, judiciary employees and 30,000 armed forces personnel. U.A.E. officials have said that none have gotten sick with Covid-19. By contrast, Western companies sought government approvals to market their candidates to the public once clinical trials were complete. China has three other Covid-19 experimental vaccines in late-stage trials. Brazil, which is testing Sinovac Biotech Ltd.’s CoronaVac, is expected to release efficacy results in the coming days. Results from early clinical trials of CoronaVac showed that it induced antibodies in volunteers, although at lower levels than those seen in people who were previously infected with Covid-19. China has had to venture overseas to conduct clinical trials on its vaccines as it has successfully controlled the coronavirus at home. Sinopharm executives have said the U.A.E. was chosen for trials due to its diverse population: Only about 10% of the country’s nearly 10 million residents are Emiratis, with the remainder largely from Asia, Europe and the U.S. Corrections & Amplifications An earlier version of this article misspelled Pfizer. Also, an earlier version of this article incorrectly identified Dubai’s ruler, Sheikh Mohammed bin Rashid Al-Maktoum, as crown prince in the photo caption. He is a former crown prince. (Corrected on Dec. 9, 2020)
🔥 最新回帖
四个面瘫怎么了？吻合群体发病率。有啥奇怪的？ 即使证实是疫苗引起的，又怎么了？面瘫这种自限性疾病，几周时间就好了。
我说的不是降解，而是mRNA进入人体后触发的永久性机能影响。 另外，我们对Pfizer疫苗志愿者中的面瘫现象有足够认识了？
国内的报告，我一个字都不会信。
我那帖是支持你的合理观点，并加以说明。
误伤友军！
等详细报告。没有详细报告，谁相信谁SB。有详细报告，看看有名有问题。一切都没有问题，看看报告谁写的。
🛋️ 沙发板凳
防疫是世界性得要不然没用。希望所有得疫苗都有用大家都能得到，在世界范围把这个控制住。
是的，希望先给国内人打上，别先紧着国外，打了疫苗就不用一有case 就搞战时状态。
当然先给国外用啊。为什么美国这么多人不愿意打疫苗？
有几个指标，100%是避免重症和死亡。 是86%有效性，还有个99%的啥，然后100%避免重症。
中国疫苗在阿联酋获批，预防中重症有效率100%-观察者网 (guancha.cn) 该疫苗对于新冠感染有86%的有效率，中和抗体的血清转换率达99%，并且对于预防中、重症感染的有效率达100%。
国药的。 科兴哪款要等巴西发
那个明显的是假新闻，有人带节奏，你也信？进去看了嘛？
诶哟。凡是中国做出来的，就是容易的。
已经澄清了，那个97%是有抗体不是有效
一个很有意思的事情是他们只批准了北京毒株做出来的灭活疫苗。很可能说明武汉毒株做出来的灭活疫苗在有效率上有差距。
搞了半天还是灭活疫苗？即使如此，中国自己是否已经正式批准国内开打？如果都有效，那么中国应当开放旅行了。
不太清楚这个Trial怎么做的，谁管理的。 谁清楚的，来介绍一下。
那个新闻是台湾民进党和大纪元造的谣言。40几个人都很久没回国了。
这个我真不知道，他们的整个过程都不是很透明
应该公布一下。
作者带中国姓的就自动站中国? 彭博好几个中国姓的记者天天报中国负面消息。WSJ又不是党媒。
Re, 要真有86%也算可以的了 .普通流感疫苗的有效性在70%左右。西方现在90% 95%的数字也未必可靠 因为这次着急其实 时间 不够长 样本 不够大 正式用起来估计有效率远远不会有 90%> .就怕 这86%都tmd的掺水的 之前号称100%有效无副作用 niub吹大了 看西方数字出来了 不敢超过西方的 但也不能搞太烂 ，数字不能太大 又略微差一点 让人觉得比较客观 .如果是这样 这尼玛的才坑人 ‘. 为了 实现领导的放卫星 弄出来的东西 假大空 这尼玛的就坑人了 . 一个人平时是个骗子 忽然会变好了 不吹牛皮 不撒谎了 。你信吗？ 希望回头是岸 坏人真的立地成佛了 。。但自己还是不要去冒险去检验真理 。还是去尝试平时就是不撒谎的人说的话 做出来的产品吧。不是说一定更好 但概率来说被坑可能性 更小。。。人命关天更是如此
阿联酋做的，应该不至于像国内那样一手遮天吧
他们前期的免疫数据是所有国产疫苗里面最好的，和康复病人的血清抗体水平接近，这个86%我觉得就算有点水分也不会差的太离谱。
还有一个不知道的信息是志愿者的年龄构成，如果都是年轻人的话意义不大。
为什么不公布一点儿具体数据，只有一个有效率。志愿者年龄组成，有没有基础疾病之类的数据应该早就有了。不会随着实验结果改变的。
你得问他们，为什么不能光明正大的
你真是。。
40多员工感染早辟谣了，那40多感染员工一直没回国，从没打过疫苗。
运输和储存没有问题。比牛津疫苗好不好要看看具体志愿者的年龄组成才能下结论
就不能科学点吗？
100%是避免重症和死亡？ 我读书少你别骗我， 你是说， 有些疫苗不是100%避免重症和死亡也有可能被批准？
疫苗好不好开发取决于病毒本事。灭活疫苗是相对成熟的技术，只要不计成本投入加快行政速度一年不到出来三期结果很正常。 美国这些公司搞什么mRNA疫苗纯粹是拿国家安全的大问题冒险，本质上还是为了自己利益。还好成功了
虽然没有第三方audit没有具体数据，还是希望有效率是真的，国内老百姓也有的打了，不然靠三家公司怎么能满足全世界尤其是中国人口需要的产量。
他说的很对。中国出的疫苗，居然要一个非洲国家来通过评定，报告成功率，又是一个鬼鬼祟祟的动作。
不是不公开透明，而是你不愿意信。 哪怕放在你眼前，你也举得是造假。
眼睛瞎了，再量的灯也没用。
你是挺无知的，当然低于100%可以被批准
首先阿联酋不是非洲国家！
其次没法在国内做的原因是国内没有做够的感染！
华人上某些人的基本知识，呵呵
灭活疫苗产量 低是个问题
有可能国内现在没有什么病例，没法做疫苗临床
对，用病毒蛋白也是
做过生化实验的都知道搞dna, rna比搞蛋白容易多了
每年流感死那么多人，流感疫苗还不是年年都打。
非常希望中国能完胜美国，那样就不用闭关锁国，那么多人回不去了
你到底对中国的疫苗新闻有没有了解？就是在这里华人上就常有亲大陆人士作为成就报道过。那个军管五毒所的女军官还公开注射表演疫苗，制造的疫苗照片都在这里看到。弄了半天连三期都一个没有做到底，还要把外国人作为实验品，真是耻辱。
中国疫苗又不会卖到美国欧洲，这里的人没人可能打，即使想打。
如果有选择的话，我会选择中国的灭活疫苗。很可惜，我们在美国恐怕没有这个选择。
SAME.
RNA 跟灭活疫苗之间，如果都有，我还是选择传统的。不过美国不可能有中国的疫苗的，连中国“发明”的口罩，都不提倡戴。
短期内看不到开放希望
真是群魔乱舞，让中国人民都打上疫苗，把国门打开才是正事，污毛们能给个时间表吗？一年还是两年，如果全国世界都开放了，你憋还锁国，不是笑话吗，这些疫苗有用吗，吹牛会死人的。
所以你的意思是怕别人不相信所以索性不公开透明？胡扯你最棒！
灭活病毒产量也不低，流感疫苗那么大量每年产得好好的。mRNA按理说应该更好产，结果到明年下半年才能实现美国普通人的接种。说白了，这些公司就是那这个机会试验这个技术，老老实实搞灭活或者重组疫苗无利可图
woyaoshou 一定知道这些对他公开的信息，今天就做一个好事，把这些疫苗在中国发展的报告及认证写在这里，让大家见识一下。
有啥没选择的。你真心要打，回中国就行，就是折腾一点。但是和自己命比起来，这些折腾都不算啥。除非你嘴上说，心里其实也没觉得中美两种疫苗真有那么大差别
多数人，并没有这个时间去折腾。
https://twitter.com/fangshimin/status/1336789393269395456
@fangshimin
《纽约时报》报道的标题是错的。中国新冠疫苗有86%有效率是国药集团给阿联酋的申报材料里说的，不是阿联酋根据当地临床试验结果。纽约时报要采访国药集团，国药集团发言人却掐了电话。这么好的事不好意思自己说？然后纽约时报又采访了伪科学骗子陶黎纳，说他是“疫苗专家”，他宣称中国疫苗马上要上市了
我不懂药物，但感觉区别很大。灭活疫苗对人体的作用是暂时的，而且其运作机制大家已经有了足够认识；mRNA疫苗对人体的影响是永久性，而且人们对它还需要进一步了解认识。
那么好，为何习近平李克强及其他常委不打，为何你不打？都要去外国找试验品？如果我说错事实，请指正。
你这种智商真的无语
不得不把外国人作为实验品，说明国内抗疫真的很成功，所以国内找不到足够病例
总比现在美国好多医院都没病床了，成天死亡新高要好
看看阿联酋通讯社怎么说的 。阿联酋正经正式批准疫苗使用了 辉瑞的疫苗也是辉瑞自己的数据，而不是FDA的数据呀....FDA是监督审查 阿布扎比，2020年12月9日(WAM)，阿联酋卫生和预防部(MOHAP)宣布，北京生物制品研究所的COVID-19灭活疫苗正式注册，这是抗击全球大流行的重要一步。该疫苗的注册是对国药集团CNBG申请的回应。这一声明是阿联酋卫生当局对这种疫苗的安全性和有效性的重要信任投票。 MOHAP与阿布扎比卫生部合作，审查了国药CNBG对三期临床试验的中期分析，结果显示北京生物制品研究所的灭活疫苗对COVID-19感染的疗效达到86%。分析还表明，该疫苗具有99%的中和抗体血清转化率，在预防中度和严重病例方面的有效性为100%。此外，分析表明没有严重的安全问题。 自9月以来，该疫苗已由MOHAP授予紧急使用授权(EUA)，以保护最易感染COVID-19的一线工作人员。阿联酋正在对其EUA项目进行授权后安全性研究(PASS)和授权后有效性研究(PAES)。这些正在进行的研究显示与中期分析相似的安全性和有效性。 第4期人类试验III包括31,000名志愿者，来自125个国家，仅在阿联酋。欧洲联盟的疫苗接种方案有效地保障了阿联酋一线工人的安全。MOHAP的北京生物制品研究所COVID-19灭活疫苗正式注册，引领了全面保护人口和负责任地开放经济的道路。翻译者：Fawzia Alaa。 https://www.wam.ae/zh-CN/details/1395302893614
你哪里看到过说100% 张口就造谣
是啊, 你竟然不知道吗?
你是不是傻X吗? 国内都没有足够的感染, 注射完怎么能知道有效还是无效啊. 这个道理都不明白, 难道用病毒去攻击这些志愿者吗?你置道德伦理于何处?
赶快给成都人打上疫苗吧，省的暴增六例鸡飞狗跳的
就给成都人打起来吧，省的航班取消，只出不进的
你眼没瞎，数据在哪里？年龄构成，滴度，人种数据在哪里？
mRNA 可以用 純生化合成的方法
完全不用養細菌病毒
美國可以成噸的生產
就怕滅菌不完全
打完就得上火方倉了
就和探月一样，高风险的活动就应该激励多个独立团体参与，公平竞争，这样才能增加共同成功的概率
过几年中国又会搞出个什么病毒来. 唉, 这玩意儿, 没法弄